Accustem Sciences Inc. (ACUT)

AccuStem Sciences began as a demerged entity from Tiziana Life Sciences plc in October 2020, carving out StemPrintER Sciences Limited as an independent clinical-stage diagnostics company focused on genomic testing for cancer patients. The new entity brought with it a portfolio of gene-expression and miRNA-based tests that had been developed to address gaps in oncology care—particularly the need for more accurate biomarker assessment in high-stakes diagnostic moments.

The company’s initial flagship product is the MSC test, a 24-microRNA assay designed to help physicians distinguish benign from malignant lung nodules detected during low-dose CT screening. Lung cancer screening programs identify thousands of nodules annually, but most are benign; the MSC test aims to reduce unnecessary biopsies and invasive follow-up procedures by providing non-invasive molecular evidence. In parallel, the company markets StemPrintER, a 20-gene prognostic assay for luminal breast cancer patients that predicts the risk of distant recurrence—information intended to guide treatment intensity and monitoring decisions.

The company pursued a strategic partnership with EmeritusDX to expand its diagnostic reach into non-invasive blood-based testing, a rapidly growing segment within precision oncology. This partnership reflected a broader industry shift toward liquid biopsies and the recognition that circulating biomarkers offer clinical and commercial advantages over tissue-based assays. By 2022, AccuStem Sciences moved to public markets, listing on the OTC under ticker ACUT, making shares accessible to a wider investor base while the company navigated the long regulatory and commercialization timeline typical of diagnostic companies.

Today, AccuStem operates as a pre-commercial or early-commercial clinical diagnostics enterprise, with its test portfolio still undergoing validation and reimbursement negotiation. The company’s evolution from a legacy subsidiary to an independent publicly traded entity reflects both the fragmentation of specialized diagnostics and the opportunity within oncology testing—a field where molecular precision continues to outpace traditional imaging and clinical judgment.

Related topics: 10-K, public-company